These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22356229)

  • 21. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.
    Johansen C; Vinter H; Soegaard-Madsen L; Olsen LR; Steiniche T; Iversen L; Kragballe K
    Br J Dermatol; 2010 Dec; 163(6):1194-204. PubMed ID: 20846304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.
    Bacchetti T; Campanati A; Ferretti G; Simonetti O; Liberati G; Offidani AM
    Br J Dermatol; 2013 May; 168(5):984-9. PubMed ID: 23614561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P; Girolomoni G
    Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis.
    Ahdout J; Haley JC; Chiu MW
    J Am Acad Dermatol; 2010 May; 62(5):874-9. PubMed ID: 19913942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of inflammatory slan (6-sulfo LacNAc) dendritic cells in psoriatic skin of patients treated with etanercept.
    Günther C; Blau K; Förster U; Viehweg A; Wozel G; Schäkel K
    Exp Dermatol; 2013 Aug; 22(8):535-40. PubMed ID: 23879812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: a pilot study.
    Piaserico S; Zattra E; Michelotto A; Alaibac M
    Acta Histochem; 2013 Sep; 115(7):767-9. PubMed ID: 23566554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with the systemic treatment of severe forms of psoriasis.
    Tichý M; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Mar; 156(1):29-40. PubMed ID: 22580858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of psoriasis with anti-TNF drugs in human immunodeficiency virus-infected patients].
    de Unamuno-Bustos B; Ballester-Sánchez R; Pérez-Ferriols A; Sánchez Carazo JL
    Med Clin (Barc); 2012 May; 138(13):593-4. PubMed ID: 22036464
    [No Abstract]   [Full Text] [Related]  

  • 34. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
    Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A
    Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
    Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
    Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
    Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.